{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ethinyl+Estradiol-Levonorgestrel+combination&page=2",
    "query": {
      "intervention": "Ethinyl Estradiol-Levonorgestrel combination",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 61,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ethinyl+Estradiol-Levonorgestrel+combination&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ethinyl+Estradiol-Levonorgestrel+combination&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T21:49:46.986Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06071442",
      "title": "Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Vemircopan",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Levonorgestrel / Ethinyl Estradiol",
          "type": "DRUG"
        },
        {
          "name": "Carbamazepine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 60,
      "start_date": "2024-01-17",
      "completion_date": "2024-04-12",
      "has_results": false,
      "last_update_posted_date": "2025-08-12",
      "last_synced_at": "2026-10-04T21:49:46.986Z",
      "location_count": 1,
      "location_summary": "Brooklyn, Maryland",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06071442"
    },
    {
      "nct_id": "NCT01170390",
      "title": "Oral Contraceptives and Body Mass Index",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Body Weight",
        "Contraceptive Usage"
      ],
      "interventions": [
        {
          "name": "All participants (Aviane)",
          "type": "DRUG"
        },
        {
          "name": "Portia",
          "type": "DRUG"
        },
        {
          "name": "Aviane",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 35 Years · Female only"
      },
      "enrollment_count": 32,
      "start_date": "2009-09",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2015-12-31",
      "last_synced_at": "2026-10-04T21:49:46.986Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01170390"
    },
    {
      "nct_id": "NCT00006324",
      "title": "Hormonal Birth Control and the Risk of Acquiring HIV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Ethinyl estradiol/levonorgestrel",
          "type": "DRUG"
        },
        {
          "name": "Medroxyprogesterone acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "16 Years to 35 Years · Female only"
      },
      "enrollment_count": 6360,
      "start_date": "1999-12",
      "completion_date": "2002-12",
      "has_results": false,
      "last_update_posted_date": "2008-08-07",
      "last_synced_at": "2026-10-04T21:49:46.986Z",
      "location_count": 1,
      "location_summary": "Research Triangle Park, North Carolina",
      "locations": [
        {
          "city": "Research Triangle Park",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006324"
    },
    {
      "nct_id": "NCT07414784",
      "title": "A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "ABBV-295",
          "type": "DRUG"
        },
        {
          "name": "Levonorgestrel/Ethinyl Estradiol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2026-02-11",
      "completion_date": "2026-08-04",
      "has_results": false,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-10-04T21:49:46.986Z",
      "location_count": 2,
      "location_summary": "Anaheim, California • Grayslake, Illinois",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Grayslake",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07414784"
    },
    {
      "nct_id": "NCT00196352",
      "title": "A Multicenter Study to Evaluate the Safety of Seasonique, an Oral Contraceptive.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Contraception"
      ],
      "interventions": [
        {
          "name": "Levonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duramed Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 320,
      "start_date": "2003-05",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2014-04-08",
      "last_synced_at": "2026-10-04T21:49:46.986Z",
      "location_count": 11,
      "location_summary": "Tucson, Arizona • Washington D.C., District of Columbia • Lincoln, Nebraska + 8 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00196352"
    },
    {
      "nct_id": "NCT07013643",
      "title": "A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "AZD6234",
          "type": "DRUG"
        },
        {
          "name": "Ethinyl estradiol/Levonorgestrel (EE/LEVO)",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen (APAP)",
          "type": "DRUG"
        },
        {
          "name": "AZD9550",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "35 Years to 75 Years · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2025-06-04",
      "completion_date": "2027-07-09",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-10-04T21:49:46.986Z",
      "location_count": 2,
      "location_summary": "Glendale, California • Brooklyn, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Brooklyn",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07013643"
    },
    {
      "nct_id": "NCT02577601",
      "title": "Impact of Combined Hormonal Contraceptives on UPA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Contraception"
      ],
      "interventions": [
        {
          "name": "Ulipristal Acetate",
          "type": "DRUG"
        },
        {
          "name": "Levonorgestrel (LNG)/Ethinyl estradiol birth control pill",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 35 Years · Female only"
      },
      "enrollment_count": 36,
      "start_date": "2015-09-08",
      "completion_date": "2017-06-17",
      "has_results": true,
      "last_update_posted_date": "2019-11-08",
      "last_synced_at": "2026-10-04T21:49:46.986Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02577601"
    },
    {
      "nct_id": "NCT01165307",
      "title": "Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Menorrhagia"
      ],
      "interventions": [
        {
          "name": "Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills",
          "type": "DRUG"
        },
        {
          "name": "Naproxen sodium pills",
          "type": "DRUG"
        },
        {
          "name": "NovaSure® Radiofrequency Endometrial Ablation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Abimbola Famuyide",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "55 Years",
        "sex": "FEMALE",
        "summary": "30 Years to 55 Years · Female only"
      },
      "enrollment_count": 77,
      "start_date": "2009-08",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2017-01-20",
      "last_synced_at": "2026-10-04T21:49:46.986Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01165307"
    },
    {
      "nct_id": "NCT01873170",
      "title": "Quantification of Immune Cells in Women Using Contraception (CHIC II)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV",
        "Immune Cells (Mucosal and Systemic)",
        "Contraception"
      ],
      "interventions": [
        {
          "name": "levonorgestrel exposure",
          "type": "DRUG"
        },
        {
          "name": "DMPA exposure",
          "type": "DRUG"
        },
        {
          "name": "etonogestrel exposure",
          "type": "DRUG"
        },
        {
          "name": "IUD insertion",
          "type": "DEVICE"
        },
        {
          "name": "subdermal contraceptive implant insertion",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "34 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 34 Years · Female only"
      },
      "enrollment_count": 326,
      "start_date": "2013-08",
      "completion_date": "2020-10",
      "has_results": false,
      "last_update_posted_date": "2021-12-27",
      "last_synced_at": "2026-10-04T21:49:46.986Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01873170"
    },
    {
      "nct_id": "NCT03630159",
      "title": "Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Large B-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Tisagenlecleucel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2018-10-09",
      "completion_date": "2021-07-20",
      "has_results": false,
      "last_update_posted_date": "2022-08-15",
      "last_synced_at": "2026-10-04T21:49:46.986Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • Chicago, Illinois • Kansas City, Kansas",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03630159"
    }
  ]
}